Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models
SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader PIN-5018 in a Phase 1 clinical trial. The first patient enrolled has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
PIN-5018 is an oral CK1α degrader developed based on the novel hypothesis of "synthetic activation of p53." The company is evaluating PIN-5018 as both a monotherapy and in multiple combination regimens. The Phase 1 study employs a dose-escalation design to assess safety, pharmacokinetics (PK), and target engagement/pharmacodynamics (PD). Pin Therapeutics also plans to expand development into additional indications.
- PIN-5018 Achieves Complete Response in ACC PDX Models
The company highlighted compelling preclinical data in ACC, a disease with no approved standard-of-care therapy. In two patient-derived xenograft (PDX) models, treatment with PIN-5018 resulted in a complete response (CR) in one model and marked tumor regression in the other, demonstrating robust antitumor activity and supporting clinical translation.
- Expansion Planned into mCRPC, Colorectal Cancer, and Other Rare Tumors
Pin Therapeutics notes that CK1α plays a key biological role in resistance mechanisms that emerge during androgen receptor (AR) inhibitor therapy. Based on this insight, the company is pursuing a strategy aimed at enabling rapid entry into the first-line (1L) setting for metastatic castration-resistant prostate cancer (mCRPC) through combination therapy with an AR signaling inhibitor (ARSI). In colorectal cancer, the company is advancing a clinical program based on the innovative concept of "synthetic activation of WNT signaling."
- Advancing Mechanism-Based Precision Oncology
Pin Therapeutics emphasized its commitment to mechanism-based precision oncology across its entire pipeline by applying sophisticated biological mechanisms. Ongoing initiatives include mode-of-action studies, integrated PK/PD analysis, and biomarker development to identify the most appropriate patient populations for each indication.
"Our goal is to leverage our innovative degradation modality and novel biological frameworks to provide meaningful therapeutic options for cancer patients with limited or no existing treatments," Pin Therapeutics CEO Hyunsun Jo said. "We look forward to demonstrating the clinical value of PIN-5018 across multiple tumor types."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
PUNE, India, April 2, 2026 /PRNewswire/ -- EKA Mobility, a leading electric vehicles and technology company, today announced a strong 5X year-on-year volume growth in FY 2025–26, with 1,143 units sold and 1,344 electric commercial vehicles produced. This milestone comes on the back of the company's comprehensive electric vehicle portfolio across segments. During the year, EKA entered the M&HCV truck segment, in addition to its existing bus and SCV portfolio. The company is a Champion OEM under the Auto PLI Scheme and has achieved certification across multiple platforms.
"FY 2025–26 is a defining year for EKA Mobility. We are not only scaling volumes but also expanding our manufacturing footprint by adding a new plant recently and increasing our planned annual capacity to 10,000 buses, 6,000 trucks and 24,000 SCVs. With the widest range of fully homologated, born-electric platforms from last-mile to long-haul, we are uniquely positioned as a full-stack EV company. Our growth across electric buses, small commercial vehicles, and now trucks validates both market demand and our execution capability.
India's transition to clean commercial mobility is accelerating, and EKA is at the forefront driving this shift at scale, with technology, innovation, and global ambition."
— Dr. Sudhir Mehta, Founder & Chairman, EKA Mobility
Strong Business Momentum Across Segments
- Electric Bus Leadership:
Secured wins under PM e-Bus Sewa and PM E-DRIVE; deployed vehicles across 15+ states including Maharashtra, Gujarat, Uttar Pradesh, Karnataka, and Delhi - SCV Breakout Year:
Strong uptake of 3S & 6S passenger vehicles and 3W cargo platforms, accelerating last-mile mobility adoption - Electric Trucks:
New Growth Engine: Entry into heavy-duty trucks contributing to growth and expanding presence in logistics electrification - Hydrogen Fuel Cell:
Deployed a 9-metre hydrogen fuel cell bus at Cochin International Airport with KPIT Technologies and BPCL; plans to deploy 15 more buses
Key Highlights:
Global Expansion:
- Commenced electric bus deployments in Africa
- Partnership with Kerchanshe Group for CKD assembly and distribution
- Agreement with NBFI Capital for manufacturing in Australia
Manufacturing Scale-Up:
- Two Pune facilities operational; Pithampur plant to be operational shortly
- Planned annual capacity: 10,000 buses, 6,000 trucks and 24,000 SCVs
Retail Network:
- Expanded dealership network; plans to add 120 dealerships in FY27
Order Book Visibility:
- 6,000+ confirmed e-buses to be delivered over the next two years
About EKA Mobility
EKA Mobility is a Pune-based electric vehicle and technology company focused on transforming India's commercial mobility landscape. With a portfolio spanning electric buses, electric trucks, and small commercial vehicles, EKA combines electric vehicle manufacturing with proprietary AI-powered fleet technology to deliver end-to-end mobility solutions.
EKA Mobility is backed by Mitsui & Co., Ltd. (Japan), VDL Groep (Netherlands), Pinnacle Industries Limited, Enam Holdings and the NIIF India-Japan Fund as equity and strategic partners and has expanded its footprint to markets in East Africa, South Africa, and Australia.
To know more about the company, kindly visit: https://ekamobility.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
EKA Mobility Achieves 5x Volume Growth
